Seeking Alpha

The $7.9B that Abbott (ABT) earned from arthritis drug Humira last year could be at risk after...

The $7.9B that Abbott (ABT) earned from arthritis drug Humira last year could be at risk after Roche's (RHHBY.PK) Actemra performed better in a trial of patients who couldn't take methotrexate. In another study, Bristol-Myers' (BMY) Orencia performed as well as Humira in patients who hadn’t taken a biological rheumatoid arthritis treatment before.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector